Hepatitis B Vaccine (Recombinant)
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC, Dynavax Technologies Corporation, Rockefeller University
Conditions
HIV InfectionsHepatitis BMeaslesPertussisPneumococcal Infections
Phase 1
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals
CompletedNCT00000633
End: 1998-10-31Target: 55Updated: 2021-11-02
A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
CompletedNCT00000745
End: 1991-05-31Target: 72Updated: 2021-11-04
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
CompletedNCT00426712
Start: 2006-01-31End: 2008-03-31Updated: 2019-03-20
Phase 3
Phase 4
Unknown Phase
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
CompletedNCT00001119
Start: 1999-10-31Target: 288Updated: 2011-03-02
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
CompletedNCT00013871
End: 2004-11-30Target: 300Updated: 2021-11-01
A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
CompletedNCT00000943
End: 2005-11-30Target: 50Updated: 2021-10-29
Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers
CompletedNCT02055365
Start: 2014-02-18End: 2015-01-06Updated: 2018-05-07